11 January 2017

NICE, 10 Spring Gardens, London

Final Agenda 

The meeting will start promptly at 10am and is expected to finish at approximately 6pm.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Code of conduct for members of the public attending the meeting – Part 1 only (open session)
  3. Apologies – Part 1 only (open session)
  4. Any other business – Part 1 only (open session)
  5. Minutes from the last Committee meeting held on 15 November 2016 – Part 1 only (open session)
  6. Appraisal of Palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer [ID915]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Chair, Dr Jane Adam – Part 1 only (open session)
    • 6.3. Presentation by the lead team, Dr Brian Shine, Professor Olivia Wu and Ms Pamela Rees – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of Obeticholic acid for treating primary biliary cirrhosis [ID785]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by the Chair, Dr Jane Adam – Part 1 only (open session)
    • 7.3. Presentation by the lead team, Dr Ian Bernstein, Mr Stephen Sharp and Ms Pamela Rees  – Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  8. Appraisal of Roflumilast for treating chronic obstructive pulmonary disease (review of technology appraisal guidance TA244) [ID984]
    • 8.1. Declarations of interest – Part 1 only (open session)
    • 8.2. Introduction by Professor Iain Squire – Part 1 only (open session)
    • 8.3. Presentation by the lead team, Professor John McMurray, Dr Rita Faria and Ms Pamela Rees – Part 1 AND part 2 (open and closed session)
    • 8.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  9. Appraisal of Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids [ID872]
    1. Declarations of interest - Part 1 only (open session)
    2. Introduction by the Chair, Dr Jane Adam - Part 1 only (open session)
    3. Presentation by the Chair, Dr Jane Adam - Part 1 AND part 2 (open and closed session)
    4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on 8 February 2017, 10am, NICE, London

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on 19 December 2016Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Josh South.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 05 to 19 December 2016
Registration is closed.